Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | MET | P08581 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 3/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29186552 | 0.86 | EGFR (0.60) | KDRPDGFRADDR2FGFR2EGFR | |
| SCHEMBL30050167 | 0.86 | EGFR (0.60) | KDRPDGFRADDR2FGFR2EGFR | |
| SCHEMBL30051204 | 0.86 | DDR2 (0.56) | KDRMETAURKALCKTEK | |
| SCHEMBL29186585 | 0.86 | DDR2 (0.56) | KDRMETAURKALCKTEK | |
| SCHEMBL29186517 | 0.85 | KDR (0.59) | KDRMETAURKALCKTEK | |
| SCHEMBL29318681 | 0.82 | DDR2 (0.54) | KDRMETAURKALCKTEK | |
| SCHEMBL30049303 | 0.82 | DDR2 (0.54) | KDRMETAURKALCKTEK | |
| SCHEMBL30702371 | 0.82 | KDR (0.56) | KDRMETAURKALCKTEK | |
| SCHEMBL29186551 | 0.79 | DDR2 (0.53) | KDRMETAURKALCKTEK | |
| SCHEMBL30050234 | 0.79 | DDR2 (0.53) | KDRMETAURKALCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | KDR 4885/4885MET 4678/4885AURKA 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.